Can brain region-selective dopamine (DA) receptor blockers preferentially act on schizophrenia subtypes?
Research Department, Ciba-Geigy, Basel, Switzerland.
S
S
Bischoff
A
A
Bruinink
F
F
Gunst
J
J
Krauss
M
M
Schaub
A
A
Vassout
L
L
Maitre
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D001552:Benzazepines / Q000494:pharmacology; D001667:Binding, Competitive / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D018492:Dopamine Antagonists; D066298:In Vitro Techniques; D051381:Rats; D011954:Receptors, Dopamine / Q000378:metabolism; D012559:Schizophrenia / Q000145:classification / Q000188:drug therapy*; D013134:Spiperone / Q000494:pharmacology
D014150:Antipsychotic Agents; D001552:Benzazepines; D018492:Dopamine Antagonists; D011954:Receptors, Dopamine; D013134:Spiperone